nach oben

Erschienen in:

10.06.2024 | Research

Second primary non-breast cancers in young breast cancer survivors

verfasst von: Bessie X. Zhang, Kristen D. Brantley, Shoshana M. Rosenberg, Gregory J. Kirkner, Laura C. Collins, Kathryn J. Ruddy, Rulla M. Tamimi, Lidia Schapira, Virginia F. Borges, Ellen Warner, Steven E. Come, Eric P. Winer, Jennifer R. Bellon, Ann H. Partridge

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 3/2024

Einloggen, um Zugang zu erhalten

Abstract

Purpose

We evaluated the incidence, timing, and risk factors for second primary non-breast cancers (SPNBC) among young breast cancer (BC) survivors.

Methods

This study included participants of the Young Women’s BC Study (YWS) who were diagnosed with stage 0-III BC between 2006 and 2016 and age 40 or younger at diagnosis (N = 1,230). Patient characteristics, treatment information, and clinical events were collected via serial surveys. Tumor and treatment data were obtained from medical record review. Five- and 10-year risks of SPNBCs were estimated via the cumulative incidence function, considering death, metastasis, or second primary BC as competing events. Fine and Gray subdistribution hazard models estimated subdistribution hazard ratios (sHRs) and 95% confidence intervals (CI) for SPNBC risk based on risk factors including demographics, germline genetics, primary BC characteristics, and treatments.

Results

Among 1,230 women, over a median follow-up of 10.1 years, 47 patients (4%) developed an SPNBC. Types of malignancy included melanoma (n = 10), thyroid (n = 10), ovarian (n = 4), sarcoma (n = 4), uterine (n = 3), rectal (n = 3), bladder (n = 2), cervical (n = 2), head/neck (n = 2), lung (n = 2), lymphoma (n = 2), pancreatic (n = 2), and renal (n = 1). Five and 10-year cumulative incidence were 1.4% and 3.2%, respectively. Median time between primary BC and SPNBC was 7.3 years. No patient factors, primary tumor characteristics, or treatments were statistically significantly associated with SPNBC in univariable or multivariable models.

Conclusion

In this population, five-year cumulative incidence was higher than that reported among healthy women under 50 years of age, highlighting the importance of long-term surveillance for new non-breast cancers in young adult BC survivors.

Murphy CC, Tortolero GA, Gerber DE, Pruitt SL (2023) An updated report on the prevalence of prior cancer among persons newly diagnosed with cancer in the surveillance, epidemiology, and end results program. JAMA Oncol. https://doi.org/10.1001/jamaoncol.2023.1723CrossRefPubMedPubMedCentral

Travis LB, Demark Wahnefried W, Allan JM, Wood ME, Ng AK (2013) Aetiology, genetics and prevention of secondary neoplasms in adult cancer survivors. Nat Rev Clin Oncol 10(5):289–301. https://doi.org/10.1038/nrclinonc.2013.41CrossRefPubMed

Berrington de Gonzalez A, Curtis RE, Kry SF et al (2011) Proportion of second cancers attributable to radiotherapy treatment in adults: a cohort study in the US SEER cancer registries. Lancet Oncol 12(4):353–360. https://doi.org/10.1016/S1470-2045(11)70061-4CrossRefPubMed

Travis LB, Ng AK, Allan JM et al (2014) Second malignant neoplasms and cardiovascular disease following radiotherapy. Health Phys 106(2):229–246. https://doi.org/10.1097/HP.0000000000000013CrossRefPubMed

Ramin C, Veiga LHS, Vo JB, Curtis RE, Bodelon C, Aiello Bowles EJ, Buist DSM, Weinmann S, Feigelson HS, Gierach GL, Berrington de Gonzalez A (2023) Risk of second primary cancer among women in the Kaiser permanente breast cancer survivors cohort. Breast Cancer Res 25(1):50. https://doi.org/10.1186/s13058-023-01647-yCrossRefPubMedPubMedCentral

Sung H, Hyun N, Leach CR, Yabroff KR, Jemal A (2020) Association of first primary cancer with risk of subsequent primary cancer among survivors of adult-onset cancers in the United States. JAMA 324(24):2521–2535. https://doi.org/10.1001/jama.2020.23130CrossRefPubMedPubMedCentral

Phua ZJ, MacInnis RJ, Jayasekara H (2022) Cigarette smoking and risk of second primary cancer: a systematic review and meta-analysis. Cancer Epidemiol 78:102160. https://doi.org/10.1016/j.canep.2022.102160CrossRefPubMed

Calip GS, Law EH, Ko NY (2015) Racial and ethnic differences in risk of second primary cancers among breast cancer survivors. Breast Cancer Res Treat 151(3):687–696. https://doi.org/10.1007/s10549-015-3439-7CrossRefPubMedPubMedCentral

McGuire V, Lichtensztajn DY, Tao L, Yang J, Clarke CA, Wu AH, Wilkens L, Glaser SL, Park SL, Cheng I (2024) Variation in patterns of second primary malignancies across U.S. race and ethnicity groups: a surveillance, epidemiology, and end results (SEER) analysis. Cancer Causes Control 35(5):799–815. https://doi.org/10.1007/s10552-023-01836-2CrossRefPubMed

10.

Brandt C, Vo JB, Gierach GL, Cheng I, Torres VN, Lawrence WR, McCullough LE, Veiga LHS, Berrington de González A, Ramin C (2024) Second primary cancer risks according to race and ethnicity among US breast cancer survivors. Int J Cancer. https://doi.org/10.1002/ijc.34971CrossRefPubMed

11.

Ghanavati M, Khorshidi Y, Shadnoush M, Akbari ME, Ardehali SH, Chavarri-Guerra Y, Akbari A, Barragan-Carrillo R, Amin Amlashi M, Javid Z, Rahmani J (2023) Tamoxifen use and risk of endometrial cancer in breast cancer patients: a systematic review and dose-response meta-analysis. Cancer Rep 6(4):e1806. https://doi.org/10.1002/cnr2.1806CrossRef

12.

Fleming CA, Heneghan HM, O’Brien D, McCartan DP, McDermott EW, Prichard RS (2018) Meta-analysis of the cumulative risk of endometrial malignancy and systematic review of endometrial surveillance in extended tamoxifen therapy. Br J Surg 105(9):1098–1106. https://doi.org/10.1002/bjs.10899CrossRefPubMed

13.

Godley LA, Larson RA (2008) Therapy-related myeloid leukemia. Semin Oncol 35(4):418–429. https://doi.org/10.1053/j.seminoncol.2008.04.012CrossRefPubMedPubMedCentral

14.

Winer ES (2020) Secondary acute myeloid leukemia: a primary challenge of diagnosis and treatment. Hematol Oncol Clin North Am 34(2):449–463. https://doi.org/10.1016/j.hoc.2019.11.003CrossRefPubMed

15.

Morton LM, Dores GM, Schonfeld SJ, Linet MS, Sigel BS, Lam CJK, Tucker MA, Curtis RE (2019) Association of chemotherapy for solid tumors with development of therapy-related myelodysplastic syndrome or acute myeloid leukemia in the modern era. JAMA Oncol 5(3):318–325. https://doi.org/10.1001/jamaoncol.2018.5625CrossRefPubMed

16.

Lee JS, DuBois SG, Coccia PF, Bleyer A, Olin RL, Goldsby RE (2016) Increased risk of second malignant neoplasms in adolescents and young adults with cancer. Cancer 122(1):116–123. https://doi.org/10.1002/cncr.29685CrossRefPubMed

17.

Sung H, Siegel RL, Hyun N, Miller KD, Yabroff KR, Jemal A (2022) Subsequent primary cancer risk among 5-year survivors of adolescent and young adult cancers. J Natl Cancer Inst 114(8):1095–1108. https://doi.org/10.1093/jnci/djac091CrossRefPubMedPubMedCentral

18.

Chao C, Bhatia S, Xu L et al (2019) Incidence, risk factors, and mortality associated with second malignant neoplasms among survivors of adolescent and young adult cancer. JAMA Netw Open 2(6):e195536. https://doi.org/10.1001/jamanetworkopen.2019.5536CrossRefPubMedPubMedCentral

19.

Chen F, Park SL, Wilkens LR et al (2022) Genetic risk of second primary cancer in breast cancer survivors: the multiethnic cohort study. Cancer Res 82(18):3201–3208. https://doi.org/10.1158/0008-5472.CAN-21-4461CrossRefPubMed

20.

Wei JL, Jiang YZ, Shao ZM (2019) Survival and chemotherapy-related risk of second primary malignancy in breast cancer patients: a SEER-based study. Int J Clin Oncol 24(8):934–940. https://doi.org/10.1007/s10147-019-01430-0CrossRefPubMed

21.

Berrington de Gonzalez A, Curtis RE, Gilbert E, Berg CD, Smith SA, Stovall M et al (2010) Second solid cancers after radiation therapy for breast cancer in SEER cancer registries. Br J Cancer 102(1):220e6. https://doi.org/10.1038/sj.bjc.6605435CrossRef

22.

Allen I, Hassan H, Joko-Fru WY, Huntley C, Loong L, Rahman T, Torr B, Bacon A, Knott C, Jose S, Vernon S, Lüchtenborg M, Pethick J, Lavelle K, McRonald F, Eccles D, Morris EJA, Hardy S, Turnbull C, Tischkowitz M, Antoniou AC (2024) Risks of second primary cancers among 584,965 female and male breast cancer survivors in England: a 25-year retrospective cohort study. Lancet Reg Health Eur 40:100903. https://doi.org/10.1016/j.lanepe.2024.100903CrossRefPubMedPubMedCentral

23.

Brantley KD, Rosenberg SM, Collins LC et al (2024) Second primary breast cancer in young breast cancer survivors. JAMA Oncol. https://doi.org/10.1001/jamaoncol.2024.0286CrossRefPubMed

24.

Guzmán-Arocho YD, Rosenberg SM, Garber JE et al (2022) Clinicopathological features and BRCA1 and BRCA2 mutation status in a prospective cohort of young women with breast cancer. Br J Cancer 126(2):302–309. https://doi.org/10.1038/s41416-021-01597-2CrossRefPubMed

25.

Lauby-Secretan B, Scoccianti C, Loomis D et al (2016) Body fatness and cancer-viewpoint of the IARC working group. N Engl J Med 375(8):794–798. https://doi.org/10.1056/NEJMsr1606602CrossRefPubMedPubMedCentral

26.

U.S. Department of Health and Human Services (2020) Smoking Cessation. A Report of the Surgeon General. Atlanta, GA: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health

27.

World Cancer Research Fund/American Institute for Cancer Research (2023) Continuous Update Project Expert Report 2018. Alcoholic drinks and the risk of cancer. wcrf.org. Accessed 23 August

28.

Fine JP, Gray RJ (1999) A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 94(446):496–509. https://doi.org/10.1080/01621459.1999.10474144CrossRef

29.

Thom B, Friedman DN, Aviki EM et al (2023) The long-term financial experiences of adolescent and young adult cancer survivors. J Cancer Surviv 17(6):1813–1823. https://doi.org/10.1007/s11764-022-01280-2CrossRefPubMed

30.

Trama A, Tittarelli A, Barigelletti G et al (2022) Excess risk of subsequent malignant neoplasms in adolescent and young adult cancer survivors: results from the first Italian population-based cohort. Cancer 128(2):364–372. https://doi.org/10.1002/cncr.33931CrossRefPubMed

31.

van der Meer DJ, van der Graaf WTA, van de Wal D, Karim-Kos HE, Husson O (2024) Long-term second primary cancer risk in adolescent and young adult (15–39 years) cancer survivors: a population-based study in the Netherlands between 1989 and 2018. ESMO Open 9(1):102203. https://doi.org/10.1016/j.esmoop.2023.102203CrossRefPubMedPubMedCentral

32.

SEER*Explorer: An interactive website for SEER cancer statistics. Surveillance Research Program, National Cancer Institute; 2023 Apr 19. Data source(s): SEER Incidence Data, November 2022 Submission (1975–2020), SEER 22 registries. https://seer.cancer.gov/statistics-network/explorer/. Accessed 18 Aug 2023.

33.

Allen I, Hassan H, Sofianopoulou E, Eccles D, Turnbull C, Tischkowitz M, Pharoah P, Antoniou AC (2023) Risks of second non-breast primaries following breast cancer in women: a systematic review and meta-analysis. Breast Cancer Res 25(1):18. https://doi.org/10.1186/s13058-023-01610-x.PMID:36765408;PMCID:PMC9912682CrossRefPubMedPubMedCentral

34.

Petrucelli N, Daly MB, Pal T (1998) BRCA1- and BRCA2-Associated Hereditary Breast and Ovarian Cancer. [Updated 2022 May 26]. In: Adam MP, Mirzaa GM, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2023. https://www.ncbi.nlm.nih.gov/books/NBK1247/

35.

Schmid-Büchi S, Halfens RJ, Dassen T, van den Borne B (2008) A review of psychosocial needs of breast-cancer patients and their relatives. J Clin Nurs 17(21):2895–2909. https://doi.org/10.1111/j.1365-2702.2008.02490.xCrossRefPubMed

36.

Schaapveld M, Visser O, Louwman MJ, de Vries EG, Willemse PH, Otter R et al (2008) Risk of new primary nonbreast cancers after breast cancer treatment: a Dutch population-based study. J Clin Oncol 26(8):1239e46. https://doi.org/10.1200/JCO.2007.11.9081CrossRef

37.

Grantzau T, Mellemkjaer L, Overgaard J (2013) Second primary cancers after adjuvant radiation therapy in early breast cancer patients: a national population based study under the danish breast cancer cooperative group (DBCG). Radiat Ther Oncol J Eur Soc Ther Radiol Oncol 106(1):42e9. https://doi.org/10.1016/j.radonc.2013.01.002CrossRef

38.

Grantzau T, Overgaard J (2015) Risk of second non-breast cancer after radiotherapy for breast cancer: a systematic review and meta-analysis of 762,468 patients. Radiother Oncol 114(1):56–65. https://doi.org/10.1016/j.radonc.2014.10.004CrossRefPubMed

39.

Burt LM, Ying J, Poppe MM, Suneja G, Gaffney DK (2017) Risk of secondary malignancies after radiation therapy for breast cancer: Comprehensive results. Breast 35:122–129. https://doi.org/10.1016/j.breast.2017.07.004CrossRefPubMed

40.

Nottage K, Lanctot J, Li Z et al (2011) Long-term risk for subsequent leukemia after treatment for childhood cancer: a report from the childhood cancer survivor study. Blood 117(23):6315–6318. https://doi.org/10.1182/blood-2011-02-335158CrossRefPubMedPubMedCentral

41.

Swerdlow AJ, Higgins CD, Smith P et al (2011) Second cancer risk after chemotherapy for Hodgkin’s lymphoma: a collaborative British cohort study. J Clin Oncol 29(31):4096–4104. https://doi.org/10.1200/JCO.2011.34.8268CrossRefPubMed

42.

Schaapveld M, Aleman BM, van Eggermond AM et al (2015) Second cancer risk up to 40 years after treatment for Hodgkin’s Lymphoma. N Engl J Med 373(26):2499–2511. https://doi.org/10.1056/NEJMoa1505949CrossRefPubMed

43.

Ng AK, Mauch PM (2009) Late effects of Hodgkin’s disease and its treatment. Cancer J 15(2):164–168. https://doi.org/10.1097/PPO.0b013e31819e30d7CrossRefPubMed

44.

Veiga LHS, Vo JB, Curtis RE, Mille MM, Lee C, Ramin C, Bodelon C, Aiello Bowles EJ, Buist DSM, Weinmann S, Feigelson HS, Gierach GL, Berrington de Gonzalez A (2022) Treatment-related thoracic soft tissue sarcomas in US breast cancer survivors: a retrospective cohort study. Lancet Oncol 23(11):1451–1464. https://doi.org/10.1016/S1470-2045(22)00561-7CrossRefPubMedPubMedCentral

45.

Clark OH, Gerend PL, Davis M, Goretzki PE, Hoffman PG Jr (1985) Estrogen and thyroid-stimulating hormone (TSH) receptors in neoplastic and nonneoplastic human thyroid tissue. J Surg Res 38(2):89–96. https://doi.org/10.1016/0022-4804(85)90012-5CrossRefPubMed

46.

Nielsen SM, White MG, Hong S et al (2016) The breast-thyroid cancer link: a systematic review and meta-analysis. Cancer Epidemiol Biomarkers Prev 25(2):231–238. https://doi.org/10.1158/1055-9965.EPI-15-0833CrossRefPubMedPubMedCentral

47.

Trinh LN, Crawford AR, Hussein MH et al (2021) Deciphering the risk of developing second primary thyroid cancer following a primary malignancy-who is at the greatest risk? Cancers 13(6):1402. https://doi.org/10.3390/cancers13061402CrossRefPubMedPubMedCentral

48.

Morris LG, Sikora AG, Tosteson TD, Davies L (2013) The increasing incidence of thyroid cancer: the influence of access to care. Thyroid 23(7):885–891. https://doi.org/10.1089/thy.2013.0045CrossRefPubMedPubMedCentral

49.

Kim J, Gosnell JE, Roman SA (2020) Geographic influences in the global rise of thyroid cancer. Nat Rev Endocrinol 16(1):17–29. https://doi.org/10.1038/s41574-019-0263-xCrossRefPubMed

50.

Li M, Dal Maso L, Vaccarella S (2020) Global trends in thyroid cancer incidence and the impact of overdiagnosis. Lancet Diabetes Endocrinol 8(6):468–470. https://doi.org/10.1016/S2213-8587(20)30115-7CrossRefPubMed

51.

Jeyakumar A, Chua TC, Lam AK, Gopalan V (2020) The melanoma and breast cancer association: an overview of their “second primary cancers” and the epidemiological, genetic and biological correlations. Crit Rev Oncol Hematol 152:102989. https://doi.org/10.1016/j.critrevonc.2020.102989CrossRefPubMed

52.

National Cancer Institute (2023) Cancer Survivors and Weight. Cancer Trends Progress Report. https://progressreport.cancer.gov/after/weight. Accessed 17 August 2023.

53.

U.S. Cancer Statistics Working Group. U.S. Cancer Statistics Data Visualizations Tool, based on 2022 submission data (1999–2020): U.S. Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute; https://www.cdc.gov/cancer/dataviz, released in November 2023.

54.

Naughton MJ, Weaver KE (2014) Physical and mental health among cancer survivors: considerations for long-term care and quality of life. N C Med J 75(4):283–286. https://doi.org/10.18043/ncm.75.4.283CrossRefPubMedPubMedCentral

55.

Ji X, Cummings JR, Gilleland Marchak J, Han X, Mertens AC (2020) Mental health among nonelderly adult cancer survivors: a national estimate. Cancer 126(16):3768–3776. https://doi.org/10.1002/cncr.32988CrossRefPubMed

56.

Yabroff KR, Lund J, Kepka D, Mariotto A (2011) Economic burden of cancer in the United States: estimates, projections, and future research. Cancer Epidemiol Biomarkers Prev 20(10):2006–2014. https://doi.org/10.1158/1055-9965.EPI-11-0650CrossRefPubMedPubMedCentral

57.

Ehsan AN, Wu CA, Minasian A et al (2023) Financial toxicity among patients with breast cancer worldwide: a systematic review and meta-analysis. JAMA Netw Open 6(2):e2255388. https://doi.org/10.1001/jamanetworkopen.2022.55388CrossRefPubMedPubMedCentral

58.

Adams SC, Herman J, Lega IC et al (2020) Young adult cancer survivorship: recommendations for patient follow-up, exercise therapy, and research. JNCI Cancer Spectr 5(1):pkaa099. https://doi.org/10.1093/jncics/pkaa099CrossRefPubMedPubMedCentral

Titel: Second primary non-breast cancers in young breast cancer survivors
verfasst von: Bessie X. Zhang
Kristen D. Brantley
Shoshana M. Rosenberg
Gregory J. Kirkner
Laura C. Collins
Kathryn J. Ruddy
Rulla M. Tamimi
Lidia Schapira
Virginia F. Borges
Ellen Warner
Steven E. Come
Eric P. Winer
Jennifer R. Bellon
Ann H. Partridge
Publikationsdatum: 10.06.2024
Verlag: Springer US
Erschienen in: Breast Cancer Research and Treatment / Ausgabe 3/2024
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-024-07400-z

Comprehensive genomic profiling of ESR1, PIK3CA, AKT1, and PTEN in HR(+)HER2(−) metastatic breast cancer: prevalence along treatment course and predictive value for endocrine therapy resistance in real-world practice

Open Access
Research

Ferroptosis as a promising targeted therapy for triple negative breast cancer

Review

Spectrum of germline pathogenic variants in Brazilian hereditary breast/ovarian cancer cases

Research

Integrating social work and shared decision-making for equity in metastatic breast cancer care

Correspondence

Barrier films or dressings for the prevention of acute radiation dermatitis in breast cancer: a systematic review and network meta-analysis

Review

Monitoring of estradiol levels in premenopausal women receiving adjuvant abemaciclib and ovarian function suppression

Brief Report

Neu im Fachgebiet Onkologie

KI-gestütztes Mammografiescreening überzeugt im Praxistest

16.01.2025
Künstliche Intelligenz im Gesundheitswesen
Nachrichten

Mit dem Einsatz künstlicher Intelligenz lässt sich die Detektionsrate im Mammografiescreening offenbar deutlich steigern. Mehr unnötige Zusatzuntersuchungen sind laut der Studie aus Deutschland nicht zu befürchten.

Welche Krebserkrankungen bei Zöliakie häufiger auftreten

16.01.2025
Zöliakie
Nachrichten

Eine große Kohortenstudie hat den Zusammenhang zwischen Zöliakie und gastrointestinalen Krebserkrankungen und inflammatorischen Krankheiten untersucht. Neben gastrointestinalen Tumoren ist auch ein nicht solider Krebs häufiger.

Adjuvanter PD-L1-Hemmer verhindert Rezidive bei Hochrisiko-Urothelkarzinom

15.01.2025
Urothelkarzinom
Nachrichten

Sind Menschen mit muskelinvasivem Urothelkarzinom für die neoadjuvante platinbasierte Therapie nicht geeignet oder sprechen sie darauf nicht gut an, ist Pembrolizumab eine adjuvante Alternative: Die krankheitsfreie Lebenszeit wird dadurch mehr als verdoppelt.

Duale Checkpointhemmung gegen Melanome verlängert langfristig das Leben

15.01.2025
Melanom
Nachrichten

Im Vergleich zu den Überlebenschancen vor der Einführung von Immuncheckpointhemmern (ICI) ist der Fortschritt durch eine ICI-Kombination mit unterschiedlichen Tagets bei fortgeschrittenem Melanom erstaunlich. Das belegen die finalen Ergebnisse der CheckMate-067-Studie und geben Betroffenen "Hoffnung auf Heilung".

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Second primary non-breast cancers in young breast cancer survivors